AgingResearch.NewsJoin free

Combined hepatocellular-cholangiocarcinoma

Disease

1 paper3 findings

  • Animals1

Interventions

2

Senolytics

downin mice1

1 study

  1. Senolytics prevent combined hepatocellular-cholangiocarcinoma in mice.

    “administration of a senolytic agent inhibited IL-6 and the development of cHCC-CCA tumors.”

    Animalsin Mdr2-KOFoxl1-CRE; RosaYFP miceliver

    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling

    Journal of hepatologyAug 18, 2022

More on Senolytics

ANTI-IL-6 antibody

downin mice1

1 study

  1. ANTI-IL-6 antibody prevents combined hepatocellular-cholangiocarcinoma in mice.

    “Administration of an anti-IL-6 antibody to Mdr2-KOFoxl1-CRE;RosaYFP mice inhibited the development of cHCC-CCA tumors.”

    Animalsin Mdr2-KOFoxl1-CRE; RosaYFP miceliver

    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling

    Journal of hepatologyAug 18, 2022

More on ANTI-IL-6 antibody

Upstream

1

IL-6 signalling

downin mice1

1 study

  1. IL-6 signalling decreases combined hepatocellular-cholangiocarcinoma in mice.

    “Blocking IL-6 trans-signaling led to a decrease in the number and size of cHCC-CCA tumors”

    Animalsin Mdr2-KOFoxl1-CRE; RosaYFP miceliver

    Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling

    Journal of hepatologyAug 18, 2022

More on IL-6 signalling

Latest

Related